Trial Profile
A Phase 2 Study of Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Nivolumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms NIVO/DARA study
- 12 May 2023 Planned End Date changed from 1 Apr 2024 to 25 Jan 2024.
- 12 Oct 2022 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 12 Oct 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2023.